Bristol-Myers Squibb’s Opdivo Receives Breakthrough Therapy Designation from FDA for Bladder Cancer

Monday, June 27, 2016

Source: Seeking Alpha

Bristol-Myers Squibb Company (NYSE:BMYannounces that the FDA has designated Opdivo (nivolumab) a Breakthrough Therapy for the treatment of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after platinum-containing chemo.

View All News »